EULAR evidence based recommendations for the management of hip osteoarthritis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Annals of the Rheumatic Diseases

Volumn 64, Issue 5, 2005, Pages 669-681

  Zhang, W ^b   Doherty, M ^b   Arden, N ^c   Bannwarth, B ^d   Bijlsma, J ^e   Gunther, K P ^f   Hauselmann, H J ^g   Herrero Beaumont, G ^h   Jordan, K ^c   Kaklamanis, P ⁱ   Leeb, B ^j   Lequesne, M ^k   Lohmander, S ^l   Mazieres, B ^m   Martin Mola, E ⁿ   Pavelka, K ^o   Pendleton, A ^p   Punzi, L ^q   Swoboda, B ^r   Varatojo, R ⁱ   Verbruggen, G ^s   Zimmermann Gorska, I ^t   Dougados, M ^a   more..

^a Hospital Cochin ^*  (France)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d HÔPITAL PELLEGRIN   (France)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h Unidad de Hepatología   (Spain)

ⁱ Stockerau Hospital ^*

^j Stockerau Hospital   (Austria)

^k Léopold Bellan Hospital   (France)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m CHU RANGUEIL   (France)

ⁿ Division de Rheumatologia   (Spain)

^o INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^p BELFAST CITY HOSPITAL   (United Kingdom)

^q UNIVERSITY OF PADOVA   (Italy)

^r UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^s GHENT UNIVERSITY HOSPITAL   (Belgium)

^t Univ of Medical Sciences   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CHONDROITIN SULFATE; CYCLOOXYGENASE 2 INHIBITOR; DIACETYLRHEIN; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOSAMINE SULFATE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYALURONIC ACID; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PIASCLEDINE; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; STEROID;

ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DYSPEPSIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEART INFARCTION; HIP OSTEOARTHRITIS; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MAXIMUM PERMISSIBLE DOSE; MEDICAL SOCIETY; META ANALYSIS; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOTOMY; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; TOTAL HIP PROSTHESIS; TREATMENT INDICATION; VISUAL ANALOG SCALE; WEIGHT REDUCTION;

EID: 20244375984     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.028886     Document Type: Article

References (113)

1. Felson DT. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev 1988;10:1-28.
2. Ingvarsson T, Hagglund G, Lohmander LS. Prevalence of hip osteoarthritis in Iceland. Ann Rheum Dis, 1999;58:201-7.
3. Lanyon P, Muir K, Doherty S, Doherty M. Assessment of a genetic contribution to osteoarthritis of the hip: sibling study. BMJ 2000;321:1179-83.
4. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States.[see comment]. Arthritis & Rheumatism 1998;41(5):778-799.
5. Tepper S, Hochberg MC. Factors associated with hip osteoarthritis: data from the First National Health and Nutrition Examination Survey (NHANES-I). Am J Epidemiol 1993;137:1081-8.
6. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.
7. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.
8. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6.
9. Hedges LV. Fitting continues models to effect size data. J Educ Stat 1982;7:245-70.
10. Cohen J. In: Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
11. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10:1665-77.
12. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
13. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
14. Rothman KJ. In: Modern epidemiology, 1st ed. Boston: Little Brown and Company, 1986.
15. Maistrelli GL, Gerundini M, Fusco U, Bombelli R, Bombelli M, Avai A. Valgus-extension osteotomy for osteoarthritis of the hip. Indications and long-term results. J Bone Joint Surg Br 1990;72:653-7.
16. Ohashi H, Hirohashi K, Yamano Y. Factors influencing the outcome of Chiari pelvic osteotomy: a long-term follow-up. J Bone Joint Surg Br 2000;82:517-25.
17. Birrell F, Afzal C, Nahit E, Lunt M, Macfarlane GJ, Cooper C, et al. Predictors of hip joint replacement in new offenders in primary care with hip pain. Br J Gen Pract 2003;53(486):26-30.
18. Dougados M, Gueguen A, Nguyen M, Berdah L, Lequesne M, Mazieres B, et al. Requirement for total hip arthroplasty: an outcome measure of hip osteoarthritis? J Rheumatol 1999;26:855-61.
19. Maillefert JF, Gueguen A, Nguyen M, Berdah L, Lequesne M, Mazieres B, et al. Relevant change in radiological progression in patients with hip osteoarthritis. I. Determination using predictive validity for total hip arthroplasty. Rheumatology (Oxford) 2002;41:142-7.
20. Maillefert JF, Gueguen A, Nguyen M, Berdah L, Lequesne M, Mazieres B, et al. A composite index for total hip arthroplasty in patients with hip osteoarthritis. J Rheumatol 2002;29:347-52.
21. Nilsdotter AK, Aurell Y, Siosteen AK, Lohmander LS, Roos HP. Radiographic stage of osteoarthritis or sex of the patient does not predict one year outcome after total hip arthroplasty. Ann Rheum Dis 2001;60:228-32.
22. Vinciguerra C, Gueguen A, Revel M, Heuleu JN, Amor B, Dougados M. Predictors of the need for total hip replacement in patients with osteoarthritis of the hip. Rev Rhum Engl Ed 1995;62:563-70.
23. Mancuso CA, Sculco TP, Salvati EA. Patients with poor preoperative functional status have high expectations of total hip arthroplasty. J Arthroplasty 2003;18:872-8.
24. Haddad FS, Garbuz DS, Chambers GK, Jagpal TJ, Masri BA, Duncan CP. The expectations of patients undergoing revision hip arthroplasty. J Arthroplasty 2001;16:87-91.
25. Superio-Cabuslay E, Ward MM, Lorig KR. Patient education interventions in osteoarthritis ana rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory drug treatment. Arthritis Care Res 1996;9:292-301.
26. Warsi A, LaValley MP, Wang PS, Avorn J, Solomon DH. Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum 2003;48:2204-13.
27. Giraudet-Le Quinfrec JS, Coste J, Vastel L, Pacault V, Jeanne L, Lamas JP, et al. Positive effect of patient education for hip surgery: A randomized trial. Clin Orthop Relat Res 2003;414:112-20.
28. Brosseou L, MacLeay L, Robinson V, Wells G, Tugwell P. Intensity of exercise for the treatment of osteoarthritis. Cochrane Database Syst Rev 2003;2:CD004259.
29. Fransen M, McConnell S, Bell M. Therapeutic exercise for people with osteoarthritis of the hip or knee. A systematic review. J Rheumatol 2002;29:1737-45.
30. Fransen M, McConnell S, Bell M. Exercise for osteoarthritis of the hip or knee. Cochrane Database Syst Rev 2003;(3):CD004286.
31. Pueit DW, Griffin MR. Published trials of nonmedicinal and noninvasive therapies for hip and knee osteoarthritis. Ann Intern Med 1994;121:133-40.
32. van Baar ME, Assendelft WJ, Dekker J, Oostendorp RA, Bijlsma JW. Effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a systematic review of randomized clinical trials. Arthritis Rheum 1999;42:1361-9.
33. Lievense AM, Bierma-Zeinstra SM, Verhagen AP, van Baar ME, Verhaar JA, Koes BW. Influence of obesity on the development of osteoarthritis of the hip: a systematic review. Rheumatology (Oxford) 2002;41:1155-62.
34. Towheed TE, Judd MJ, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2003;(2):CD004257.
35. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004;63:901-7. doi.-10.1136/ard.2003.018531 [Published Online First 5 March 2004].
36. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6.
37. Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis Rheum 2002;46:3046-54.
38. Lewis SC, Langman MJS, Laporte J-R, Matthres NS, Rawlins MD, Wiholm B-E. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54:320-6.
39. Jerussi TP, Caubet J-F, McCray JE, Handley DA. Clinical endoscopic evaluation of the gastroduodenal tolerance to (R)- ketoprofen, (R)-flurbiprofen, racemic ketoprofen, and paracetamol: a randomized, single-blind, placebo-controlled trial. J Clin Pharmacol 1998;38(suppl 2):19-24S.
40. Lanza FL, Codispati JR, Nelson EB. An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen. Am J Gastroenterol 1998;93:1051-4.
41. Muller P, Simon B, Weise D, Dammann HG. Endoscopic studies on the gastric tolerance following 6 days treatment of paracetamol and acetylsalicylic acid. A placebo-controlled double-blind-study in the healthy volunteers. [In German.] Arzneimittelforschung 1990;40:316-18.
42. Barrett BJ. Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Am J Kidney Dis 1996;28(suppl 1):14-19.
43. Rexrodo KM, Buring JE, Glynn RJ, Stampfer MJ, Youngman LD, Gaziano JM. Analgesic use and renal function in men. JAMA 2001;286:315-21.
44. Zhang W. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Safety 2001;24:1127-42.
45. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001;345:1801-8.
46. Kamath CC, Kremers HM, Vanness DJ, O'Fallon WM, Cabanela RL, Gabriel SE. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 2003;6:144-57.
47. Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, nonsteroidal anti-inflammatory drugs for osteoarthritis of the hip. [Review] [17 refs]. Cochrane Database Syst Rev 2000;(2):CD000517.
48. Bollini P, Garcia Rodriguez LA, Perez Gutthann S, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992;152:1289-95.
49. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115(10):787-96.
50. Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:30-4S.
51. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12.
52. Tramer MR, Moore RA, Reynolds DJM, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82.
53. Desks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619-23.
54. Rostom A, Dube C, Jolicoeur E, Baucher M, Joyce J. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office tor Health Technology Assessment, 2004 (Technology overview 12.).
55. Capurso L, Koch M. [Prevention of NSAID-induced gastric lesions: H2 antagonists or misoprostol? A meta-analysis of controlled clinical studies]. [In Italian]. Clin Ter 1991;139:179-89.
56. Leandro G, Pilotto A, Franceschi M, Bertin T, Lichino E, Di Mario F. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001 ;46:1924-36.
57. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: A cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000;27:2203-14.
58. Shield MJ. Diclofenac/misoprostol: novel findings and their clinical potential. J Rheumatol 1998;25(suppl 51):31-41.
59. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
60. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993;36:447-59.
61. Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin Ther 2001;23:1061-79.
62. de Craen AJM, Di Giulio G, Lampe-Schoenmaeckers, Kessels AGH, Kleijnen J. Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review. BMJ 1996;313:321-5.
63. Peloso PM, Bellamy N, Bensen W, Thomson GT, Harsanyi Z, Babul N, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000;27:764-71.
64. Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004;31:150-6.
65. Kjaersgaard-Andersen P, Nafei A, Skov O, Madsen F, Andersen HM, Kroner K, et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double-blind, multi-centre study. Pain 1990;43:309-18.
66. Parr G, Darekar B, Fletcher A, Bulpitt CJ. Joint pain and quality of life; results of a randomised trial. Br J Clin Pharmacol 1989;27:235-42.
67. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis.[comment]. JAMA 2000;283(11):1469-75.
68. Towheed TE, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001;(1):CD002946.
69. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000;27:205-11.
70. Conrozier T, Vignon E. Die Wirkung von chondroitisulfat bei der behandlung der huftgelenksarthrose eine doppelblindstudie gegen placebo. Lit Rheumatol 1992;14:69-75.
71. Pavelka K, Gatterova J, Gollerova V, Urbanova Z, Sedlackova M, Altman RD. A 5-yeor randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage 2000;8:335-42.
72. Little CV, Parsons T. Herbal therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001;(1):CD002947.
73. Long L, Soeken K, Ernst E. Herbal medicines for the treatment of osteoarthritis: a systematic review. Rheumatology (Oxford) 2001;40:779-93.
74. Blotman F, Maheu E, Wulwik A, Caspard H, Lopez A. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed 1997;64:825-34.
75. Maheu E, Mazieres B, Valat JP, Loyau G, Le Loet X, Bourgeois P, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 1998;41:81-91.
76. Lequesne M, Maheu E, Cadet C, Dreiser RL. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 2002;47:50-8.
77. Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum 2001;44:2539-47.
78. Fagnani F, Bouvenot G, Valat JP, Bardin T, Berdah L, Lafuma A, et al. Medico-economic analysis of diacerein with or without standard therapy in the treatment of osteoarthritis. Pharmacoeconomics 1998;13:135-46.
79. Brocq O, Tran G, Breuil V, Grisot C, Flory P, Euller-Ziegler L. Hip osteoarthritis: short-term efficacy and safety of viscosupplementation by hylan G-F 20. An open-label study in 22 patients. Joint Bone Spine 2002;69:388-91.
80. Vad VB, Sakalkale D, Sculco TP, Wickiewicz TL. Role of hylan G-F 20 in treatment of osteoarthritis of the hip joint. Arch Phys Med Rehabil 2003;84:1224-6.
81. Conrozier T, Bertin P, Mathieu P, Chariot J, Bailleul F, Treves R, et al. Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open-label, multicentre, pilot study. Clin Exp Rheumatol 2003;21:605-10.
82. Flanagan J, Casale FF, Thomas TL, Desai KB. Intra-articular injection for pain relief in patients awaiting hip replacement. Ann R Coll Surg Engl 1988;70:156-7.
83. Plant MJ, Borg AA, Dziedzic K, Saklatvala J, Dawes PT. Radiographic patterns and response to corticosteroid hip injection. Ann Rheum Dis 1997;56:476-80.
84. Waseem M, Sadiq S, Gambhir AK, Lim J, Maxwell S, Bamford DJ. Safety and efficacy of intra-articular injection of the hip. Hip International 2002;12:378-82.
85. Murphy S, Deshmukh R. Periacetabular osteotomy: preoperative radiographic predictors of outcome. Clin Orthop Relat Res 2002;405:168-74.
86. Takatori Y, Ninomiya S, Nakamura S, Morimoto S, Moro T, Nagai I. Long-term results of rotational acetabufar osteotomy in young patients with advanced osteoarthrosis of the hip. J Orthop Sci 2000;5:336-41.
87. Takatori Y, Ninomiya S, Nakamura S, Morimoto S, Moro T, Nagai I, et al. Long-term results of rotational acetabular osteotomy in patients with slight narrowing of the joint space on preoperative radiographic findings. J Orthop Sci 2001;6:137-40.
88. Tönnis D, Arning A, Bloch M, Heineche A, Kalohschmidt K. Triple pelvic osteotomy. J Pediatr Orthop 1994;3:53-67.
89. Yasunaga Y, Takahashi K, Ochi M, Ikuta Y, Hisatome T, Nakashiro J, et al. Rotational acetabular osteotomy in patients forty-six years of age or older: Comparison with younger patients. J Bone Joint Surg Am 2003;85:266-72.
90. Hasegawa Y, Iwase T, Kitamura S, Yamauchi KK, Sakano S, Iwata H. Eccentric rotational acetabular osteotomy for acetabular dysplasia: follow-up of one hundred and thirty-two hips for five to ten years. J Bone Joint Surg Am 2002;84:404-10.
91. Siebenrock KA, Leunig M, Ganz R. Periacetabular osteotomy: the Bernese experience. J Bone Joint Surg Am 2001;83:449-55.
92. Helenius I, Tanskanen P, Haapala J, Niskanen R, Remes V, Mokka R, et al. Hip arthroscopy in osteoarthritis. A review of 68 patients. Ann Chirurg Gynaecol 2001;90:28-31.
93. Margheritini F, Villar RN. The efficacy of arthroscopy in the treatment of hip osteoarthritis. Chir Organi Mov 1999;84:257-61.
94. Beck M, Leunig M, Parvizi J, Boutier V, Wyss D, Ganz R. Anterior femoroacetabular impingement: part II. Midterm results of surgical treatment. Clin Orthop Relat Res 2004;418:67-73.
95. Ganz R, Gill TJ, Gautier E, Ganz K, Krugel N, Berlemann U. Surgical dislocation of the adult hip: a technique with full access to the femoral head and acetabulum without the risk of avascular necrosis. J Bone Joint Surg Br 2001;83:1119-24.
96. Faulkner A, Kennedy LG, Baxter K, Donovan J, Wilkinson M, Bevan G. Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model. Health Technol Assess 1998;2:1-133.
97. Fitzpatrick R, Shortall E, Sculpher M, Murray D, Morris R, Lodge M, et al. Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technol Assess 1998;2:1-64.
98. Kawasaki M, Hasegawa Y, Sakano S, Torii Y, Warashina H. Quality of life after several treatments for osteoarthritis of the hip. J Orthop Sci 2003;1:32-5.
99. Nilsdotter A-K, Petersson IF, Roos EM, Lohmander LS. Predictors of patient relevant outcome after total hip replacement for osteoarthritis: a prospective study. Ann Rheum Dis 2003;62:923-30.
100. Visuri T, Pulkkinen P, Turula KB, Paavolainen P, Koskenvuo M. Life expectancy after hip arthroplasty. Case-control study of 1018 cases of primary arthrosis. Acta Orthop Scand 1994;65:9-11.
101. Dolin SJ, Williams AC, Ashford N, George J, Pereira L, Perello A. Factors affecting medical decision-making in patients with osteoarthritis of the hip: Allocation of surgical priority. Disabil Rehabil 2003;25:771-7.
102. Chang RW, Pellisier JM, Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA 1996;275:858-65.
103. O'Shea K, Bale E, Murray P. Cost analysis of primary total hip replacement. Irish Med J 2002;95:177-80.
104. Rorabeck CH, Bourne RB, Laupacis A, Feeny D, Wong C, Tugwell P, et al. A double-blind study of 250 cases comparing cemented with cementless total hip arthroplasty. Cost-effectiveness and its impact on health-related quality of life. Clin Orthop Relat Res 1994;298:156-64.
105. NIH consensus conference. Total hip replacement. NIH Consensus Development Panel on Total Hip Replacement. JAMA 1995;273:1950-6.
106. Maillefert JF, Gueguen A, Nguyen M, Berdah L, Lequesne M, Mazieres B, et al. A composite index for total hip arthroplasty in patients with hip osteoarthritis. J Rheumatol 2002;29:347-52.
107. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis: Part I. Osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40.
108. Kwoh CK, Anderson LG, Greene JM, Johnson DA, O'Dell JR, Robbins ML, et al. Guidelines for the management of rheumatoid arthritis: 2002 update - American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Arthritis Rheum 2002;46:328-46.
109. Scott DL. Guidelines for the diagnosis, investigation and management of osteoarthritis of the hip and knee. J R Col Physicians Lond 1993;27:391-6.
110. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:637-9.
111. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights-Part 1: The disease and its risk factors. Ann Intern Med 2000;133:635-46.
112. Black N. Evidence-based surgery: a passing fad? World J Surg 1999;23:789-93.
113. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-18.